Esperion Therapeutics (ESPR) Short Interest Ratio & Short Volume $1.17 -0.03 (-2.50%) Closing price 04:00 PM EasternExtended Trading$1.19 +0.02 (+1.62%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Esperion Therapeutics Short Interest DataEsperion Therapeutics (ESPR) has a short interest of 26.34 million shares, representing 13.54% of the float (the number of shares available for trading by the public). This marks a -5.76% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.8, indicating that it would take 4.8 days of the average trading volume of 5.28 million shares to cover all short positions.Current Short Interest26,340,000 sharesPrevious Short Interest27,950,000 sharesChange Vs. Previous Month-5.76%Dollar Volume Sold Short$22.50 millionShort Interest Ratio4.8 Days to CoverLast Record DateMay 31, 2025Outstanding Shares198,199,000 sharesFloat Size194,580,000 sharesShort Percent of Float13.54%Today's Trading Volume2,145,207 sharesAverage Trading Volume5,278,274 sharesToday's Volume Vs. Average41% Short Selling Esperion Therapeutics? Sign up to receive the latest short interest report for Esperion Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartESPR Short Interest Over TimeESPR Days to Cover Over TimeESPR Percentage of Float Shorted Over Time Esperion Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/202526,340,000 shares $22.50 million -5.8%13.5%4.8 $0.85 5/15/202527,950,000 shares $21.72 million -6.4%14.4%5.2 $0.78 4/30/202529,860,000 shares $29.84 million -0.6%15.3%6.4 $1.00 4/15/202530,030,000 shares $29.90 million +7.2%15.4%6.6 $1.00 3/31/202528,020,000 shares $40.35 million -3.0%14.4%6.4 $1.44 3/15/202528,900,000 shares $43.35 million -0.8%14.9%6.8 $1.50 2/28/202529,140,000 shares $49.54 million +3.7%14.9%5.4 $1.70 2/15/202528,100,000 shares $52.27 million -10.1%14.4%5.1 $1.86 1/31/202531,240,000 shares $55.92 million -8.1%16.0%5 $1.79 1/15/202533,980,000 shares $75.10 million +5.0%17.4%5.6 $2.21 Get the Latest News and Ratings for ESPR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/202432,350,000 shares $71.17 million +27.0%16.6%5.7 $2.20 12/15/202425,470,000 shares $57.31 million -16.5%13.1%4.6 $2.25 11/30/202430,490,000 shares $85.37 million -2.4%15.6%6.7 $2.80 11/15/202431,250,000 shares $66.25 million -6.6%16.0%8.2 $2.12 10/31/202433,460,000 shares $68.26 million -5.5%17.2%8.8 $2.04 10/15/202435,390,000 shares $75.38 million -5.6%18.2%9.7 $2.13 9/30/202437,470,000 shares $61.83 million -1.6%19.3%9.3 $1.65 9/15/202438,090,000 shares $72.75 million -5.8%19.6%6.9 $1.91 8/31/202440,440,000 shares $74.01 million -3.1%20.8%6.4 $1.83 8/15/202441,730,000 shares $82.21 million +9.4%21.5%6 $1.97 7/31/202438,140,000 shares $88.10 million -3.3%22.2%5.1 $2.31 7/15/202439,420,000 shares $98.55 million +67.4%25.5%4.8 $2.50 6/30/202423,550,000 shares $52.28 million -5.4%15.2%2.8 $2.22 6/15/202424,890,000 shares $74.42 million +13.7%16.1%3 $2.99 5/31/202421,890,000 shares $47.28 million -12.1%14.2%2.8 $2.16 5/15/202424,910,000 shares $57.29 million +25.4%16.1%3.4 $2.30 4/30/202419,870,000 shares $39.14 million +6.8%11.8%2.9 $1.97 4/15/202418,600,000 shares $35.99 million -6.6%11.0%3 $1.94 3/31/202419,920,000 shares $53.39 million +12.7%11.8%3 $2.68 3/15/202417,670,000 shares $36.58 million +4.3%10.5%2.8 $2.07 2/29/202416,950,000 shares $42.54 million -8.7%10.0%2.8 $2.51 2/15/202418,570,000 shares $49.40 million -7.5%11.0%3 $2.66 1/31/202420,070,000 shares $42.95 million -0.6%11.9%3.3 $2.14 1/15/202420,200,000 shares $61.00 million +1.4%17.9%3.7 $3.02 12/31/202319,920,000 shares $59.56 million +9.2%17.7%4.3 $2.99 12/15/202318,240,000 shares $33.20 million +2.8%16.2%4.3 $1.82 11/30/202317,740,000 shares $23.59 million -3.1%15.7%4.6 $1.33 11/15/202318,310,000 shares $21.06 million +0.5%16.2%4.7 $1.15 10/31/202318,220,000 shares $15.10 million -5.2%17.2%4.8 $0.83 10/15/202319,220,000 shares $15.95 million -3.0%18.1%5 $0.83Watch This Robotics Demo Before July 23rd (Ad)Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry." Click here to watch the demo… 9/30/202319,810,000 shares $19.41 million +20.4%18.7%5.5 $0.98 9/15/202316,460,000 shares $23.37 million +8.4%15.5%4.7 $1.42 8/31/202315,180,000 shares $24.29 million +8.5%14.3%4.8 $1.60 8/15/202313,990,000 shares $22.94 million +4.3%13.2%5 $1.64 7/31/202313,410,000 shares $21.05 million +2.9%12.7%4.9 $1.57 7/15/202313,030,000 shares $18.76 million +4.2%13.9%5.4 $1.44 6/30/202312,510,000 shares $17.39 million -9.9%13.3%5.1 $1.39 6/15/202313,880,000 shares $19.02 million +3.8%14.8%5 $1.37 5/31/202313,370,000 shares $18.18 million -8.4%14.3%3.6 $1.36 5/15/202314,600,000 shares $24.82 million No Change15.6%3.5 $1.70 10/31/202214,030,000 shares $114.06 million +5.3%N/A11.6 $8.13 10/15/202213,330,000 shares $101.31 million +6.6%N/A11.5 $7.60 9/30/202212,500,000 shares $83.75 million -0.9%N/A12.1 $6.70 9/15/202212,610,000 shares $94.83 million -5.5%N/A12.6 $7.52 8/31/202213,350,000 shares $99.59 million +8.6%N/A13.9 $7.46 8/15/202212,290,000 shares $81.97 million -1.8%N/A13.7 $6.67 7/31/202212,520,000 shares $72.24 million +3.2%N/A12.9 $5.77 7/15/202212,130,000 shares $81.39 million +2.6%N/A11.8 $6.71 6/30/202211,820,000 shares $75.18 million +6.8%N/A10.2 $6.36 6/15/202211,070,000 shares $59.00 million -4.2%N/A9.1 $5.33 5/31/202211,560,000 shares $65.89 million +13.7%N/A8.7 $5.70 5/15/202210,170,000 shares $58.78 million +15.8%N/A7.3 $5.78 4/30/20228,780,000 shares $49.87 million +10.0%N/A6.4 $5.68 4/15/20227,980,000 shares $47.00 million +8.7%N/A6.3 $5.89 3/31/20227,340,000 shares $34.06 million +36.7%N/A0 $4.64 3/15/20225,370,000 shares $24.70 million +29.7%N/A4 $4.60 2/28/20224,140,000 shares $16.93 million +18.0%N/A2.7 $4.09 2/15/20223,510,000 shares $14.00 million +11.4%N/A1.6 $3.99 1/31/20223,150,000 shares $13.51 million -3.7%N/A1.4 $4.29 1/15/20223,270,000 shares $12.85 million -62.2%N/A1.5 $3.93 12/31/20218,650,000 shares $43.25 million +10.6%N/A3.9 $5.00 12/15/20217,820,000 shares $41.84 million -20.9%N/A3.8 $5.35 11/30/20219,880,000 shares $86.25 million +11.5%N/A5.2 $8.73 11/15/20218,860,000 shares $77.26 million -3.5%N/A8.1 $8.72 10/29/20219,180,000 shares $82.07 million +15.2%N/A9.5 $8.94 10/15/20217,970,000 shares $72.85 million +8.7%28.7%9.3 $9.14 9/30/20217,330,000 shares $88.33 million -10.0%26.4%9.7 $12.05 9/15/20218,140,000 shares $92.31 million +0.5%29.3%11.4 $11.34 8/31/20218,100,000 shares $105.46 million -7.1%29.2%14.1 $13.02 8/13/20218,720,000 shares $121.30 million -3.3%31.4%15.4 $13.91 7/30/20219,020,000 shares $138.82 million -5.1%32.5%14.5 $15.39 7/15/20219,500,000 shares $167.96 million +5.2%34.3%14.1 $17.68 6/30/20219,030,000 shares $190.98 million +0.9%32.6%13.7 $21.15 6/15/20218,950,000 shares $221.96 million -0.4%32.3%14.2 $24.80 5/28/20218,990,000 shares $178.99 million -1.5%32.4%13.8 $19.91 5/14/20219,130,000 shares $204.51 million -5.8%N/A13.4 $22.40 4/30/20219,690,000 shares $264.63 million -0.8%40.8%14.1 $27.31 4/15/20219,770,000 shares $265.26 million +3.3%N/A14 $27.15 3/31/20219,460,000 shares $259.58 million -3.1%N/A12.1 $27.44 3/15/20219,760,000 shares $296.12 million -3.5%N/A11.7 $30.34Watch This Robotics Demo Before July 23rd (Ad)Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry." Click here to watch the demo… 2/26/202110,110,000 shares $279.84 million +5.9%N/A12.2 $27.68 2/12/20219,550,000 shares $293.57 million -5.8%35.5%11.7 $30.74 1/29/202110,140,000 shares $325.70 million -8.5%37.7%12.3 $32.12 1/15/202111,080,000 shares $296.39 million +2.8%N/A12.9 $26.75 12/31/202010,780,000 shares $303.46 million +6.5%N/A15.7 $28.15 12/15/202010,120,000 shares $299.35 million +3.5%44.0%15.5 $29.58 11/30/20209,780,000 shares $264.26 million +0.9%42.5%16 $27.02 11/15/20209,690,000 shares $278.01 million -3.7%42.1%15.2 $28.69 10/30/202010,060,000 shares $315.48 million -0.7%43.7%16.3 $31.36 10/15/202010,130,000 shares $342.19 million -9.1%N/A17.5 $33.78 9/30/202011,140,000 shares $414.07 million -0.3%N/A18.6 $37.17 9/15/202011,170,000 shares $414.74 million -3.5%N/A18 $37.13 8/31/202011,570,000 shares $417.68 million +5.1%N/A17.6 $36.10 8/14/202011,010,000 shares $361.24 million +1.2%40.9%16.2 $32.81 7/31/202010,880,000 shares $409.41 million +3.8%40.7%15.8 $37.63 7/15/202010,480,000 shares $496.96 million +3.5%39.2%16.3 $47.42 6/30/202010,130,000 shares $482.59 million +8.1%37.9%15.4 $47.64 6/15/20209,370,000 shares $411.81 million +15.4%35.1%13.6 $43.95 ESPR Short Interest - Frequently Asked Questions What is Esperion Therapeutics' current short interest? Short interest is the volume of Esperion Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 31st, investors have sold 26,340,000 shares of ESPR short. 13.54% of Esperion Therapeutics' shares are currently sold short. Learn More on Esperion Therapeutics' current short interest. What is a good short interest ratio for Esperion Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ESPR shares currently have a short interest ratio of 5.0. Learn More on Esperion Therapeutics's short interest ratio. Which institutional investors are shorting Esperion Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Esperion Therapeutics: Walleye Trading LLC, Walleye Capital LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Esperion Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.54% of Esperion Therapeutics' floating shares are currently sold short. Is Esperion Therapeutics' short interest increasing or decreasing? Esperion Therapeutics saw a drop in short interest in May. As of May 31st, there was short interest totaling 26,340,000 shares, a drop of 5.8% from the previous total of 27,950,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Esperion Therapeutics' float size? Esperion Therapeutics currently has issued a total of 198,199,000 shares. Some of Esperion Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Esperion Therapeutics currently has a public float of 194,580,000 shares. How does Esperion Therapeutics' short interest compare to its competitors? 13.54% of Esperion Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Esperion Therapeutics: Gyre Therapeutics, Inc. (8.73%), Day One Biopharmaceuticals, Inc. (24.86%), Vir Biotechnology, Inc. (12.93%), Anavex Life Sciences Corp. (33.06%), Arbutus Biopharma Co. (7.01%), Evolus, Inc. (16.26%), KalVista Pharmaceuticals, Inc. (14.06%), AnaptysBio, Inc. (34.78%), Cogent Biosciences, Inc. (13.77%), AbCellera Biologics Inc. (10.20%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks. What does it mean to sell short Esperion Therapeutics stock? Short selling ESPR is an investing strategy that aims to generate trading profit from Esperion Therapeutics as its price is falling. ESPR shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Esperion Therapeutics? A short squeeze for Esperion Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ESPR, which in turn drives the price of the stock up even further. How often is Esperion Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ESPR, twice per month. The most recent reporting period available is May, 31 2025. More Short Interest Resources from MarketBeat Related Companies Gyre Therapeutics Short Squeeze Day One Biopharmaceuticals Short Squeeze Vir Biotechnology Short Squeeze Anavex Life Sciences Short Squeeze Arbutus Biopharma Short Squeeze Evolus Short Squeeze KalVista Pharmaceuticals Short Squeeze AnaptysBio Short Squeeze Cogent Biosciences Short Squeeze AbCellera Biologics Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ESPR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
